CatalYm
Munich, Germany · Biotechnology, Health Care · 57 employees
CatalYm is developing visugromab, a first-in-class anti-GDF-15 antibody, in solid tumors and other indications. In its first-in-human Phase 1/2a study, visugromab demonstrated durable anti-tumor efficacy with long-lasting objective responses in relapsed and refractory metastatic solid tumor patients in combination with anti-PD-1 treatment. In addition, data from the same study demonstrated that vi
Funding history
- Series series d — $150.0M — Jul 2024
- Series series c — $50.0M — Nov 2022
Recent signals
- Jun 09, 2026: CatalYm Appoints Peter Garcia as Chief Financial Officer
- Sep 15, 2025: CatalYm Appoints Clinton Musil as Chief Financial Officer and Sujata Rao as Chief Medical Officer
- Jan 09, 2025: CatalYm Appoints Scott Clarke as Chief Executive Officer
- Dec 10, 2024: Launched CatalYm Announces Potential of Visugromab to Treat Cachexia in Cancer Patients at International SCWD Conference.
- Jul 16, 2024: Raised $150.0M in Series series d
- Nov 22, 2022: Raised $50.0M in Series series c
See plans & pricing → Track CatalYm’s funding, hiring, and signals — with verified contacts — on Fundz.